The Treatment of Hidradenitis Suppurativa Evaluation 糖心原创 (THESEUS)
The THESEUS team includes people with hidradenitis suppurativa, dermatologists, GPs, surgeons and research experts.
Hidradenitis suppurativa is a long term, painful skin condition that affects approximately 1% of adults. It involves boils in areas such as the armpits and groins. The THESEUS study was developed to inform the design of future hidradenitis suppurativa trials and to help understand how hidradenitis suppurativa treatments are currently used. The study was developed with the support of the UK Dermatology Clinical Trials Network
THESEUS was collaborative study being led by the at Cardiff University.
Key information
What did THESEUS involve?
THESEUS investigated five treatments: two medicines (doxycycline, clindamycin & rifampicin), two types of surgery (deroofing and excision), and laser treatment. Further details about what each of these treatment choices entails can be found in the treatment decision grid.
The choice of treatment was decided by the participant and their doctor, and depended upon what treatment is available locally and severity of disease.
For further details, please see the patient information leaflet.
Who took part in the study?
Participants were
- 18 years of age or older
- Had a diagnosis of active hidradenitis suppurativa not controlled by current treatment.
Where did the study take place?
| Barnsley |
|---|
| Broomfield Hospital |
|---|
| Cardiff |
|---|
| Forth Valley |
|---|
| Guys and St Thomas |
|---|
| Newcastle |
|---|
| Oxford |
|---|
| Salisbury |
|---|
| Stoke Mandeville |
|---|
The research was funded by the UK Government, through the National Institute of Health Research Health Technology Assessment (NIHR HTA) programme.
Videos
These videos contain scenes of surgical procedures.
Links
Publications
Leighton P, Howells L, Bates J, Gibbons A, Cannings-John R, Collier F, Evans J, Harris C, Hood K, Howes R, Riaz M, Rodrigues J, Stanton H, Thomas-Jones E, Thomas K, Ingram JR. Br J Dermatol. 2023 May 18:ljad152. doi: 10.1093/bjd/ljad152. Online ahead of print.
John R Ingram, Janine Bates, Rebecca Cannings-John, Fiona Collier, Judith Evans, Angela Gibbons, Ceri Harris, Laura Howells, Kerenza Hood, Rachel Howes, Paul Leighton, Muhammad Riaz, Jeremy Rodrigues, Helen Stanton, Kim S Thomas, Emma Thomas-Jones, British Journal of Dermatology, 2023;, ljad388,
Bates J, Stanton H, Cannings-John R, Thomas KS, Leighton P, Howells LM, Rodrigues J, Howes R, Collier F, Harris C, Gibbons A, Thomas-Jones E, Hood K, Ingram JR.
BMJ Open. 2022 Apr 21;12(4):e060815. doi: 10.1136/bmjopen-2022-060815.
Howes, R., J. R. Ingram, K. S. Thomas, F. Collier, and J. N. Rodrigues.J Plast Reconstr Aesthet Surg. 2021.
Collier, F., R. Howes, J. Rodrigues, K. S. Thomas, P. Leighton, and J. R. Ingram. BJGP Open. 5, no. 5, 2021.
Howells, L., N. Lancaster, M. McPhee, C. Bundy, J. R. Ingram, P. Leighton, K. Henaghan-Sykes, and K. S. Thomas. Br J Dermatol. 185, no. 5 921-34, 2021.
Population-based Clinical Practice Research Datalink studyusing algorithm modelling to identify the true burden of hidradenitis suppurativa
J.R. Ingram et al. British Journal of Dermatology (2018)
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process
L. Thorlacius and J.R. Ingram et al. British Journal of Dermatology (2018)
Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality
J.R. Ingram et al. British Journal of Dermatology (2016)
J.R. Ingram et al. British Journal of Dermatology (2014)
This study is funded by the National Institute for Health Research (NIHR) [Health Technology Assessment Programme (HTA Project: 17/98/01)]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.